BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16682734)

  • 1. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
    Calvo E; Baselga J
    J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer.
    Edelman MJ
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S3-8. PubMed ID: 16459173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
    Jänne PA
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
    Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
    Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.
    Mitsudomi T; Yatabe Y
    Cancer Sci; 2007 Dec; 98(12):1817-24. PubMed ID: 17888036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor mutations in lung cancer.
    Sharma SV; Bell DW; Settleman J; Haber DA
    Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
    Zhou CC; Deng XF
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
    [No Abstract]   [Full Text] [Related]  

  • 14. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.
    Tsao AS; Papadimitrakopoulou V
    Clin Lung Cancer; 2013 Jul; 14(4):311-21. PubMed ID: 23582282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.
    Bencardino K; Manzoni M; Delfanti S; Riccardi A; Danova M; Corazza GR
    Intern Emerg Med; 2007 Mar; 2(1):3-12. PubMed ID: 17551677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of growth factor signalling.
    Wakeling AE
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
    Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
    PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
    Zalcman G
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S5-6. PubMed ID: 17242635
    [No Abstract]   [Full Text] [Related]  

  • 19. Lung cancer in never smokers: change of a mindset in the molecular era.
    Lee YJ; Kim JH; Kim SK; Ha SJ; Mok TS; Mitsudomi T; Cho BC
    Lung Cancer; 2011 Apr; 72(1):9-15. PubMed ID: 21272954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race, gender and mutations in the prediction of anti-EGFR activity.
    Jimeno A
    Future Oncol; 2005 Apr; 1(2):201-4. PubMed ID: 16555991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.